



Alzinova: Change in the management team

Alzinova AB (publ) ("Alzinova" or the "Company") announces today a change in the management team, Chief Medical Officer (CMO) Anders Bylock has announced that he wishes to leave the company for personal reasons and has today announced his resignation and that his last day is May 28, 2023. The Company has previously initiated a recruitment process to find a replacement.

Chief Medical Officer (CMO) Anders Bylock, has today announced that he will make his last day at Alzinova on May 28, 2023. Anders has previously announced that he wishes to leave the Company for personal reasons sometime in 2023 and Alzinova had previously initiated a recruitment process to find a replacement. That work is progressing, and the Company is now trying to accelerate the recruitment process as a result of Anders leaving already at the end of May 2023. The tasks that Anders Bylock has had will, during a transition period, be covered by Alzinova's management team and medical advisors.

CEO Kristina Torfgård comments:

"We are very sad that Anders Bylock is leaving us at Alzinova and fully understand his decision. A dialog has been conducted during the year and we expected the decision to come, hence we had already initiated a recruitment process to find a replacement. Anders has been an important part of the management team and the team and contributed a lot to the development during the four years he has worked with us. We would like to extend our warmest thanks for Anders' efforts!"

Resigning CMO Anders Bylock comments:

"It has been very exciting and fun to work at Alzinova together with the team. Unfortunately, I have to prioritize retirement and health, so I am not able to stay on. I look forward to following the progress from the sidelines and seeing the next generation of Alzheimer's drugs being developed."

For more information, please contact:

Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.



About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments

Alzinova: Change in the management team